MIND MEDICINE MINDMED INC (MNMD) Fundamental Analysis & Valuation

NASDAQ:MNMD • CA60255C8850

Current stock price

15.02 USD
+0.15 (+1.01%)
At close:
14.9 USD
-0.12 (-0.8%)
After Hours:

This MNMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MNMD Profitability Analysis

1.1 Basic Checks

  • MNMD had negative earnings in the past year.
  • In the past year MNMD has reported a negative cash flow from operations.
  • MNMD had negative earnings in each of the past 5 years.
  • MNMD had a negative operating cash flow in each of the past 5 years.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of MNMD (-70.95%) is worse than 71.73% of its industry peers.
  • MNMD has a Return On Equity of -128.72%. This is in the lower half of the industry: MNMD underperforms 66.49% of its industry peers.
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MNMD Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MNMD has more shares outstanding
  • The number of shares outstanding for MNMD has been increased compared to 5 years ago.
  • The debt/assets ratio for MNMD has been reduced compared to a year ago.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.86 indicates that MNMD is not in any danger for bankruptcy at the moment.
  • MNMD's Altman-Z score of 3.86 is fine compared to the rest of the industry. MNMD outperforms 68.06% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that MNMD is not too dependend on debt financing.
  • The Debt to Equity ratio of MNMD (0.31) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.86
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 3.30 indicates that MNMD has no problem at all paying its short term obligations.
  • MNMD has a Current ratio (3.30) which is comparable to the rest of the industry.
  • MNMD has a Quick Ratio of 3.30. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
  • MNMD has a Quick ratio (3.30) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MNMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 13.27% over the past year.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 20.08% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.31%
EPS Next 2Y5.17%
EPS Next 3Y7%
EPS Next 5Y20.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MNMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
  • Also next year MNMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.17%
EPS Next 3Y7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNMD Dividend Analysis

5.1 Amount

  • No dividends for MNMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNMD Fundamentals: All Metrics, Ratios and Statistics

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (1/14/2026, 8:00:01 PM)

After market: 14.9 -0.12 (-0.8%)

15.02

+0.15 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners41.21%
Inst Owner Change41.94%
Ins Owners0.78%
Ins Owner Change-2.12%
Market Cap1.48B
Revenue(TTM)N/A
Net Income(TTM)-168.10M
Analysts84.21
Price Target29.16 (94.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.53%
Min EPS beat(2)-52.55%
Max EPS beat(2)-34.51%
EPS beat(4)1
Avg EPS beat(4)-23.85%
Min EPS beat(4)-52.55%
Max EPS beat(4)27.56%
EPS beat(8)3
Avg EPS beat(8)-25.48%
EPS beat(12)5
Avg EPS beat(12)-13.29%
EPS beat(16)8
Avg EPS beat(16)-7.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.5%
PT rev (3m)14.33%
EPS NQ rev (1m)2.31%
EPS NQ rev (3m)2.38%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)-15.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.33
P/tB 13.37
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.33
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z 3.86
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
EPS Next Y-1.31%
EPS Next 2Y5.17%
EPS Next 3Y7%
EPS Next 5Y20.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.13%
EBIT Next 3Y-20.36%
EBIT Next 5Y19.82%
FCF growth 1Y-101.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.12%
OCF growth 3YN/A
OCF growth 5YN/A

MIND MEDICINE MINDMED INC / MNMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MIND MEDICINE MINDMED INC?

ChartMill assigns a fundamental rating of 2 / 10 to MNMD.


What is the valuation status for MNMD stock?

ChartMill assigns a valuation rating of 0 / 10 to MIND MEDICINE MINDMED INC (MNMD). This can be considered as Overvalued.


Can you provide the profitability details for MIND MEDICINE MINDMED INC?

MIND MEDICINE MINDMED INC (MNMD) has a profitability rating of 0 / 10.


What is the financial health of MIND MEDICINE MINDMED INC (MNMD) stock?

The financial health rating of MIND MEDICINE MINDMED INC (MNMD) is 5 / 10.